I watched with high interest the webcast from the last ESC congress http://spo.escardio.org/SessionDetails.aspx?id=398931#.UEiARUSHdRA and also read the paper on the NEJM (Pubmed ID 22920912). After a careful analysis of those data I think it is NOT the time to exclude IABP from the treatment of cardiogenic shock; also the trial, although well designed, has some limitation as also some very important details are overlooked.

I'd like to hear your thoughts about it.

More Giacomo Bianchi's questions See All
Similar questions and discussions